Research
Antidepressants and Sweating: Incidence by Drug Class
Excessive sweating is a well-recognized side effect of antidepressants. On FDA prescribing labels, it is reported in roughly 5–14% of people taking SSRIs and up to 21% for some SNRIs at higher doses. This page compiles the label-reported incidence figures by drug and class, drawn directly from FDA prescribing information. These percentages come from separate clinical trials and are not comparable head to head. This is verified label information, not medical advice, and not a basis for starting, stopping, or changing any medication.
Published 2026-07-12 · Last reviewed 2026-07-12 · Educational information, not medical advice.
Key statistics at a glance
up to 21%
reported hyperhidrosis with desvenlafaxine (SNRI) at 400 mg, versus 4% on placebo — clearly dose-related
Pristiq FDA label
11.4%
sweating (including night sweats) with venlafaxine ER, versus 2.9% on placebo
Effexor XR FDA label
5–14%
reported sweating across SSRIs, depending on drug and indication
FDA labels (see table)
~4–22%
review-level estimate for antidepressant-induced sweating overall
Marcy & Britton 2005 (secondary)
A recognized class effect
Antidepressants that affect serotonin and noradrenaline signaling — SSRIs, SNRIs, and older tricyclics — are all recognized causes of excessive sweating. It shows up on prescribing labels under several different terms: "hyperhidrosis," "sweating," "sweating increased," or, in one case, "sweating (including night sweats)." Knowing which term a label uses matters when looking up a specific drug.
The figures below are adverse-reaction incidences reported in the FDA-approved labels. Each comes from that drug's own clinical trials.
Reported sweating incidence by drug
Every figure below is from the current FDA label for that drug. The percentages reflect different indications, doses, and trial populations — they are for reference, not for ranking one drug against another.
| Drug | Class | Reported incidence (label term) | Source |
|---|---|---|---|
| Desvenlafaxine | SNRI | 10% (50 mg) → 21% (400 mg) vs 4% placebo — "hyperhidrosis" | FDA label |
| Venlafaxine ER | SNRI | 11.4% vs 2.9% — "sweating (incl. night sweats)" | FDA label |
| Duloxetine | SNRI | 6% vs 1% — "hyperhidrosis" | FDA label |
| Paroxetine | SSRI | 5–14% by indication (panic 14%, MDD 11%) — "sweating" | FDA label |
| Citalopram | SSRI | 11% vs 9% — "sweating increased" | FDA label |
| Fluoxetine | SSRI | 8% vs 3% (MDD) — "sweating" | FDA label |
| Sertraline | SSRI | 7% vs 3% — "hyperhidrosis" | FDA label |
| Escitalopram | SSRI | 5% vs 2% (MDD) — "sweating increased" | FDA label |
| Bupropion SR | NDRI | 5–6% vs 2% — "sweating" | FDA label |
| Amitriptyline | TCA | "increased perspiration" listed; no incidence given | FDA label |
Placebo comparison shown where the label reports it. Terms and denominators differ by drug.
Label incidence at a glance
The chart shows a representative label figure for each drug. Read it as "what each drug's own trials reported," not as a ranking — the trials differ.
| Group | Value |
|---|---|
| Desvenlafaxine (up to) | 21% |
| Paroxetine (up to) | 14% |
| Venlafaxine ER | 11.4% |
| Citalopram | 11% |
| Fluoxetine | 8% |
| Sertraline | 7% |
| Duloxetine | 6% |
| Bupropion SR | 6% |
| Escitalopram | 5% |
Source: FDA prescribing labels via DailyMed. Chart is an original rendering of the cited data.
Why these percentages can't be ranked against each other
It is tempting to read the table as "desvenlafaxine is worst, escitalopram is safest," but that is not what the numbers support. Each figure comes from a different set of trials, with different patients, indications, doses, and even different definitions of the side effect. Citalopram is a good example: its 11% sweating rate sits against a 9% placebo rate — a two-point difference — while sertraline's 7% sits against 3% placebo. The absolute label number reflects the trial population, not the drug's relative risk.
The dependable takeaways are qualitative: sweating is a common, recognized effect across antidepressant classes; SNRIs tend to report the highest rates; and for at least one drug (desvenlafaxine) the effect is clearly dose-related.
Tricyclics and the overall estimate
Tricyclic antidepressant labels (such as amitriptyline) list "increased perspiration" as an adverse reaction but do not give an incidence percentage, so no reliable number can be quoted for them. At the class level, review articles estimate that antidepressant-induced excessive sweating affects roughly 4% to 22% of users — a range consistent with the individual drug figures above. These review estimates are secondary sources and are best read as broad context.
Methodology and limitations
Drug-level incidence figures were taken directly from current FDA prescribing labels via the National Library of Medicine's DailyMed. The overall 4–22% range comes from review articles (secondary). Each figure was traced to its source.
Limitations: FDA-label adverse-event rates come from that drug's own clinical trials and reflect specific indications, doses, durations, and patient populations, so they cannot be compared head to head or used to rank drugs by risk. Labels use different terms ("hyperhidrosis," "sweating," "sweating increased") and different placebo comparators. Tricyclic labels report the effect without a percentage. This page is verified label information for general education only — it is not medical advice and not a basis for starting, stopping, or changing any medication; medication decisions should be made with a prescribing clinician.
Frequently asked questions
- Which antidepressant classes most commonly cause sweating?
- On FDA labels, SNRIs show the highest reported rates (venlafaxine ER 11.4%, desvenlafaxine up to 21% at high dose), followed by SSRIs (roughly 5–14% depending on the drug and indication). Bupropion is lower (5–6%). Tricyclic labels list increased perspiration but give no percentage.
- Is the sweating dose-related?
- For desvenlafaxine the label shows a clear dose response, from about 10% at 50 mg up to 21% at 400 mg. Citalopram's label also notes a positive dose relationship. Most other labels report a single pooled figure.
- What term should I look for on a drug label?
- It varies. Newer labels use "hyperhidrosis" (sertraline, duloxetine, desvenlafaxine); others use "sweating" or "sweating increased" (paroxetine, fluoxetine, citalopram, escitalopram, bupropion); venlafaxine's label specifies "sweating (including night sweats)."
- Citalopram shows 11% — does that mean it causes more sweating than sertraline's 7%?
- No. Citalopram's 11% is against a 9% placebo rate (a two-point difference), while sertraline's 7% is against 3% placebo. Absolute label numbers reflect each trial's population, not relative risk, which is exactly why they can't be ranked head to head.
- How common is antidepressant-induced sweating overall?
- Review-level estimates put it at roughly 4–22% of users, consistent with the individual drug figures. Those are secondary estimates offered as broad context.
- Is this medical advice?
- No. These are verified FDA-label figures for information only. They are not comparable head to head and are not a basis for starting, stopping, or changing medication — those decisions belong with a prescribing clinician.
Sources
Primary peer-reviewed studies and official sources first, then reviews and institutional framing (secondary).
- US Food and Drug Administration / DailyMed. Prescribing information (adverse reactions): Pristiq (desvenlafaxine), Effexor XR (venlafaxine), Cymbalta (duloxetine), Paxil (paroxetine), Celexa (citalopram), Prozac (fluoxetine), sertraline, Lexapro (escitalopram), Wellbutrin SR (bupropion). DailyMed, National Library of Medicine. DailyMed
- Marcy TR, Britton ML. Antidepressant-induced sweating. Ann Pharmacother. 2005;39(4):748–752 — review estimate ~4–22%. (secondary) PubMed
- Cheshire WP, Fealey RD. Drug-induced hyperhidrosis and hypohidrosis: incidence, prevention and management. Drug Saf. 2008;31(2):109–126. (secondary) PubMed
How to cite this page
Sweat Explained. Antidepressants and Sweating: Incidence by Drug Class. Published 2026-07-12; last reviewed 2026-07-12. Available at: https://sweatexplained.com/research/antidepressants-and-sweating
Please cite the original studies for the underlying figures. Journalists are welcome to link to this page; the charts are original renderings of the cited data.